Dumas Anaëlle, Couvreur Patrick
Institut Galien Paris-Sud , Université Paris-Sud , UMR CNRS 8612 , Faculté de Pharmacie , 5 rue Jean-Baptiste Clément , 92296 Châtenay-Malabry Cedex , France . Email:
Chem Sci. 2015 Apr 16;6(4):2153-2157. doi: 10.1039/c5sc00070j. Epub 2015 Jan 19.
Metal nanostructures offer invaluable possibilities for targeted drug delivery, detection/diagnosis and imaging. Whereas iron, gold, silver and platinum nanoarchitectures have largely dominated this field to date, several hurdles impede the widespread application of those nanopharmaceuticals in a clinical context. Therefore, technologies based on alternative metals are now being evaluated for their potential in medical applications. Palladium nanostructures are characterized by remarkable catalytic and optical properties. However, until recently, very few studies have taken advantage of these unique characteristics for applications in the biomedical field. Very recently, palladium nanostructures have been reported as prodrug activator, as photothermal agents and for anti-cancer/anti-microbial therapy. With only a handful of reports available, the pharmaceutical applications of palladium nanostructures reviewed here are in their infancy. Yet their interesting performance and toxicity profiles may qualify them as future key players in the nanomedical field.
金属纳米结构为靶向药物递送、检测/诊断及成像提供了极有价值的可能性。尽管迄今为止铁、金、银和铂纳米结构在该领域占据主导地位，但仍有一些障碍阻碍了这些纳米药物在临床环境中的广泛应用。因此，目前正在评估基于其他金属的技术在医学应用中的潜力。钯纳米结构具有显著的催化和光学特性。然而，直到最近，很少有研究利用这些独特特性应用于生物医学领域。最近，有报道称钯纳米结构可作为前药激活剂、光热剂以及用于抗癌/抗菌治疗。由于仅有少量报道，本文所综述的钯纳米结构的药物应用尚处于起步阶段。然而，它们有趣的性能和毒性特征可能使它们成为纳米医学领域未来的关键参与者。
